Health
Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection – News-Medical.Net
Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Enzyme linked immunosorbent assays (“ELISAs”) are very common research tools used to detect and quantify a target of interest in a wide range of samples. Using the same Affimer reagents that are incorporated into its rapid coronavirus saliva test…
-
General14 hours agoMore buses without dedicated lanes likely after Gold Coast light rail plan scrapped
-
Business20 hours agoBuy this monthly high-yield ETF instead
-
Noosa News18 hours agoRain across far west NSW brings hope to graziers
-
Noosa News19 hours agoClive Palmer’s lawyer Sam Iskander ‘misplaced’ $2.5m in gold bullion, court told